General Announcement::Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
25-Jan-2018 11:30:47
Status
New
Announcement Sub Title
Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody
Announcement Reference
SG180125OTHRU0RP
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
25/01/2018 08:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

SGX_PR_2501.pdf
Total size =3221K